Company facts
- Industry
- Pharmaceutical Preparations
- Headquarters
- Boston, Massachusetts
- Most recent report
- 10-Q, filed Aug 12, 2026
- Incorporated
- Delaware
- Filings on record
- 60 filings
- On EDGAR
- CIK 1540171
- Fiscal year ends
- December
- Filer status
- Non-accelerated filer Smaller reporting company Emerging growth company
Financials 2
News 5
Prospectuses and Registrations 5
Ownership 8 of 36
- SCHEDULE 13G Large holder reported a passive stake Aug 14, 2026
- SCHEDULE 13G Large holder reported a passive stake Aug 11, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 6, 2026
- SCHEDULE 13D Large holder reported an active stake May 8, 2026
- SCHEDULE 13D Large holder reported an active stake May 8, 2026
- SCHEDULE 13G Large holder reported a passive stake May 7, 2026
- 4 Insider reported a trade May 5, 2026
- SCHEDULE 13G Large holder reported a passive stake May 5, 2026
Other 8 of 12
- EFFECT Notice that a registration became effective Apr 29, 2026
- CERT Exchange certified a listing Apr 29, 2026
- 8-A12B Registration of a security for exchange listing Apr 27, 2026
- DRS/A Draft registration statement, submitted confidentially, amended Mar 18, 2026
- DRS Draft registration statement, submitted confidentially Feb 6, 2026
- D Oct 10, 2023
- D May 8, 2020
- D/A Amended filing May 24, 2017
Everything here comes from Avalyn Pharma Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour.